Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Objectives Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an increasing
incidence and prevalence because of progressively aging populations. Costs related to AF …

Aim Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an
alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF) …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …

Atrial fibrillation (AF) and subsequent stroke and death have become major public health
problems in China. Oral anticoagulant (OAC) forms the backbone of prevention of AF-related …

Background Ablation-based treatment has emerged as an alternative rhythm control strategy
for symptomatic atrial fibrillation (AF). Recent studies have demonstrated the cost …

Objective Warfarin has a narrow therapeutic window and large variability in dosing that are
affected by clinical and genetic factors. To help guide the dosing of warfarin, the Clinical …

Background This study aimed to assess the cost-effectiveness of non-vitamin K antagonist
oral anticoagulants (NOACs) in comparison with warfarin using data from real practice …

Purpose This study aims to conduct a comprehensive cost-effectiveness comparison
between novel oral anticoagulants (NOACs) and warfarin in Chinese patients with left …

We aimed to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model from
healthy Chinese subjects and real-world non-valvular atrial fibrillation (NVAF) patients. We …